Role of Ferredoxin 1 (FDX1) in cancer and its therapeutic potential

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Cancer Pathogenesis and Therapy

• Publication date

  2025-11-01

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/j.cpt.2025.11.002PMCID PMC12992101
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• NUDT21 lactylation reprograms alternative polyadenylation to promote cuproptosis resistance

  2025cited by this paper
• Copper-mediated SEC14L3 promotes cuproptosis to inhibit hepatocellular carcinoma growth via ERK/YY1/FDX1 axis

  2025cited by this paper
• HMGB1 regulates the activation of dendritic cells and CD4+ T cell responses through the modulation of autophagy in bleomycin-induced pulmonary fibrosis.

  2025cited by this paper
• FDX1 promotes elesclomol-induced PANoptosis in diffuse large B-cell lymphoma via activating IRF3/IFN-β signaling

  2025cited by this paper
• Radiotherapy promotes cuproptosis and synergizes with cuproptosis inducers to overcome tumor radioresistance.

  2025cited by this paper
• An up‐To‐Date Review of Elesclomol and Its Nano‐Formulations in Cancer Therapy

  2025cited by this paper
• FDX1 Regulates the Phosphorylation of ATM, DNA-PKcs Akt, and EGFR and Affects Radioresistance Under Severe Hypoxia in the Glioblastoma Cell Line T98G

  2025cited by this paper
• o8G-modified circKIAA1797 promotes lung cancer development by inhibiting cuproptosis

  2025cited by this paper
• Modulating ovarian cancer progression through FDX1-driven autophagy

  2025cited by this paper
• FDX1 overexpression inhibits the growth and metastasis of clear cell renal cell carcinoma by upregulating FMR1 expression

  2025cited by this paper
• Cuproptosis inhibits tumor progression and enhances cisplatin toxicity in ovarian cancer

  2025cited by this paper
• Upregulation of miR-3130-5p Enhances Hepatocellular Carcinoma Growth by Suppressing Ferredoxin 1 : miR-3130-5p Enhances HCC Growth via Inhibiting FDX1.

  2025cited by this paper
• Knocking Down Ferredoxin 1 Inhibits the Progression of Colorectal Cancer and Regulates Cuproptosis via Mediating the Hippo Signaling Pathway

  2025cited by this paper
• AKT1 Phosphorylates FDX1 to Promote Cuproptosis Resistance in Triple‐Negative Breast Cancer

  2025cited by this paper
• Insights on the crosstalk among different cell death mechanisms

  2025cited by this paper
• Long non-coding RNA SNHG7 as a key driver of colorectal cancer proliferation and metastasis by inhibiting cuproptosis

  2025cited by this paper
• Hippo/YAP signaling pathway in colorectal cancer: regulatory mechanisms and potential drug exploration

  2025cited by this paper
• Janus Hydrogels Delivering Low-Density Lipoprotein Receptor-Related Protein 6 Inhibitor Enhance Myocardial Repair via m6A-Dependent Cuproptosis in Bama Pigs.

  2025cited by this paper
• Molecular function validation and prognostic value analysis of the cuproptosis-related gene ferredoxin 1 in papillary thyroid carcinoma

  2025cited by this paper
• LncRNA PVT1 promotes cuproptosis through transcriptional activation of FDX1 in colorectal cancer

  2025cited by this paper
• Cuproptosis-Related Gene FDX1 Induces Malignant Progression and Immune Suppression in Triple-Negative Breast Cancer.

  2025cited by this paper
• Copper ionophore complex ES-Cu synergizes with quercetin to target FDX1, promote cuproptosis, and reverse lenvatinib resistance in hepatocellular carcinoma cells.

  2025cited by this paper
• FDX1 facilitates elesclomol-induced cuproptosis and promotes glioblastoma development via transcription factor NFKB1.

  2025cited by this paper
• Nanoparticles induced cuproptosis to enhance antitumor immunotherapy

  2025cited by this paper
• Engineered RAP-anchored copper-escorting liposomes for FDX1-targeted cuproptosis in glioblastoma therapy

  2025cited by this paper
• Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy

  2024cited by this paper
• Role of hippo pathway and cuproptosis-related genes in immune infiltration and prognosis of skin cutaneous melanoma

  2024cited by this paper
• Involvement of copper in cell death and cancer

  2024cited by this paper
• Anti-FDX1 Autoantibody as a Potential Biomarker for Non-Small Cell Lung Cancer Detection.

  2024cited by this paper
• The Hippo Pathway in Breast Cancer: The Extracellular Matrix and Hypoxia

  2024cited by this paper
• Prognostic value of FDX1, the cuprotosis key gene, and its prediction models across imaging modalities and histology

  2024cited by this paper
• Comprehensive analysis of the expression level, prognostic value, and immune infiltration of cuproptosis-related genes in human breast cancer

  2024cited by this paper
• Copper-coordinated nanomedicine for the concurrent treatment of lung cancer through the induction of cuproptosis and apoptosis.

  2024cited by this paper
• The Epigenetic Hallmarks of Cancer.

  2024cited by this paper
• A cuproptosis nanocapsule for cancer radiotherapy

  2024cited by this paper
• Metabolic heterogeneity in cancer

  2024cited by this paper
• Cancer resistance and metastasis are maintained through oxidative phosphorylation.

  2024cited by this paper
• Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy

  2024cited by this paper
• A cuproptosis-related gene expression signature predicting clinical prognosis and immune responses in intrahepatic cholangiocarcinoma detected by single-cell RNA sequence analysis

  2024cited by this paper
• Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor Immunotherapy

  2024cited by this paper
• Apoptosis and cuproptosis Co-activated Copper-based metal-organic frameworks for cancer therapy

  2024cited by this paper
• Repositioning fluphenazine as a cuproptosis-dependent anti-breast cancer drug candidate based on TCGA database.

  2024cited by this paper
• FDX1 downregulation activates mitophagy and the PI3K/AKT signaling pathway to promote hepatocellular carcinoma progression by inducing ROS production

  2024cited by this paper
• The Role of Cuproptosis Key Factor FDX1 in Gastric Cancer.

  2024cited by this paper
• Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death

  2024cited by this paper
• Ferredoxin 1: a gatekeeper in halting lung adenocarcinoma progression through activation of the GPRIN2 signaling pathway

  2024cited by this paper
• Curcuminoid PBPD induces cuproptosis and endoplasmic reticulum stress in cervical cancer via the Notch1/RBP‐J/NRF2/FDX1 pathway

  2024cited by this paper
• A phase 1/2 study of disulfiram and copper with concurrent radiation therapy and temozolomide for patients with newly diagnosed glioblastoma.

  2024cited by this paper
• A comprehensive and systematic analysis of Dihydrolipoamide S-acetyltransferase (DLAT) as a novel prognostic biomarker in pan-cancer and glioma

  2024cited by this paper
• Integrated profiling identifies ferredoxin 1 as an immune-related biomarker of malignant phenotype in glioma

  2024cited by this paper
• FDX1 inhibits thyroid cancer malignant progression by inducing cuprotosis

  2023cited by this paper
• Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration

  2023cited by this paper
• Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma

  2023cited by this paper
• 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer.

  2023cited by this paper
• FDX1 regulates cellular protein lipoylation through direct binding to LIAS

  2023cited by this paper
• FDX1-dependent and independent mechanisms of elesclomol-mediated intracellular copper delivery

  2023cited by this paper
• Autophagy and autophagy-related pathways in cancer

  2023cited by this paper
• The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression

  2023cited by this paper
• The FDX1 methylation regulatory mechanism in the malignant phenotype of glioma.

  2023cited by this paper
• Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma

  2023cited by this paper
• FDX1 enhances endometriosis cell cuproptosis via G6PD-mediated redox homeostasis

  2023cited by this paper
• Expression of Ferredoxin1 in cisplatin‑resistant ovarian cancer cells confers their resistance against ferroptosis induced by cisplatin

  2023cited by this paper
• Prognostic and immunological role of FDX1 in pan-cancer: an in-silico analysis

  2023cited by this paper
• A Novel Oncogenic Role of FDX1 in Human Melanoma Related to PD-L1 Immune Checkpoint

  2023cited by this paper
• Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer

  2023cited by this paper
• Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1

  2023cited by this paper
• Insights into recent findings and clinical application of YAP and TAZ in cancer

  2023cited by this paper
• Construction and validation of a novel cuproptosis-mitochondrion prognostic model related with tumor immunity in osteosarcoma

  2023cited by this paper
• Integrated analyses reveal the prognostic, immunological features and mechanisms of cuproptosis critical mediator gene FDX1 in KIRC

  2023cited by this paper
• Lipoylation is dependent on the ferredoxin FDX1 and dispensable under hypoxia in human cells

  2023cited by this paper
• A cuproptosis-related gene signature and associated regulatory axis in stomach adenocarcinoma based on bioinformatics analysis

  2023cited by this paper
• Glutarate regulates T cell metabolism and anti-tumour immunity

  2023cited by this paper
• Ferredoxin 1 is essential for embryonic development and lipid homeostasis

  2023cited by this paper
• Adrenomedullin/FOXO3 enhances sunitinib resistance in clear cell renal cell carcinoma by inhibiting FDX1 expression and cuproptosis

  2023cited by this paper
• FDX1 is required for the biogenesis of mitochondrial cytochrome c oxidase in mammalian cells.

  2023cited by this paper
• Lactylation of METTL16 promotes cuproptosis via m6A-modification on FDX1 mRNA in gastric cancer

  2023cited by this paper
• Comprehensive analysis of cuproptosis genes and cuproptosis-related genes as prognosis factors in esophageal squamous cell carcinoma.

  2023cited by this paper
• SREBF1/SREBP-1 concurrently regulates lipid synthesis and lipophagy to maintain lipid homeostasis and tumor growth

  2023cited by this paper
• Identification of a novel cuproptosis‐related gene signature for multiple myeloma diagnosis

  2023cited by this paper
• LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma.

  2023cited by this paper
• Comprehensive analysis of the role of cuproptosis-related genes in the prognosis and immune infiltration of adrenocortical Carcinoma

  2023cited by this paper
• Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma

  2023cited by this paper
• METTL3 promotes non-small-cell lung cancer growth and metastasis by inhibiting FDX1 through copper death-associated pri-miR-21-5p maturation.

  2023cited by this paper
• Combination of the cuproptosis inducer disulfiram and anti-PD-L1 abolishes NSCLC resistance by ATP7B to regulate the HIF-1 signaling pathway

  2023cited by this paper
• Ferredoxin reductase and p53 are necessary for lipid homeostasis and tumor suppression through the ABCA1–SREBP pathway

  2022cited by this paper
• Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment

  2022cited by this paper
• Multi-omics pan-cancer study of cuproptosis core gene FDX1 and its role in kidney renal clear cell carcinoma

  2022cited by this paper
• Establishment and experimental validation of a novel cuproptosis-related gene signature for prognostic implication in cholangiocarcinoma

  2022cited by this paper
• Cuproptosis key gene FDX1 is a prognostic biomarker and associated with immune infiltration in glioma

  2022cited by this paper
• Mitochondrial [2Fe‐2S] ferredoxins: new functions for old dogs

  2022cited by this paper
• Functional spectrum and specificity of mitochondrial ferredoxins FDX1 and FDX2

  2022cited by this paper
• High expression of cuproptosis-related gene FDX1 in relation to good prognosis and immune cells infiltration in colon adenocarcinoma (COAD)

  2022cited by this paper
• Characterization of the functional effects of ferredoxin 1 as a cuproptosis biomarker in cancer

  2022cited by this paper
• Cuproptosis-related gene FDX1 expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma

  2022cited by this paper
• Ferredoxin 1 is a cuproptosis-key gene responsible for tumor immunity and drug sensitivity: A pan-cancer analysis

  2022cited by this paper
• Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance

  2022cited by this paper
• Caspase-1 and Gasdermin D Afford the Optimal Targets with Distinct Switching Strategies in NLRP1b Inflammasome-Induced Cell Death

  2022cited by this paper
• Copper induces cell death by targeting lipoylated TCA cycle proteins

  2022cited by this paper
• mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment

  2022cited by this paper
• The hallmarks of cancer metabolism: Still emerging.

  2022cited by this paper

• No citing papers are available for this paper.